CINECA IRIS Institutional Research Information System

BUDA, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.122
AS - Asia 5.081
EU - Europa 4.401
SA - Sud America 836
AF - Africa 240
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 8
Totale 21.709
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.807
IT - Italia 1.679
SG - Singapore 1.585
CN - Cina 1.526
HK - Hong Kong 935
BR - Brasile 694
SE - Svezia 685
DE - Germania 587
BG - Bulgaria 353
VN - Vietnam 269
GB - Regno Unito 255
TR - Turchia 247
CA - Canada 238
RU - Federazione Russa 196
FI - Finlandia 150
UA - Ucraina 128
IN - India 118
FR - Francia 88
CI - Costa d'Avorio 85
BD - Bangladesh 67
JP - Giappone 61
KR - Corea 61
CH - Svizzera 57
AT - Austria 53
AR - Argentina 48
MX - Messico 36
IQ - Iraq 34
SN - Senegal 33
ID - Indonesia 27
SA - Arabia Saudita 26
ZA - Sudafrica 26
PK - Pakistan 25
PL - Polonia 25
BE - Belgio 24
NL - Olanda 23
NG - Nigeria 21
VE - Venezuela 20
ES - Italia 19
MA - Marocco 19
AU - Australia 17
CO - Colombia 16
EG - Egitto 16
UZ - Uzbekistan 16
EC - Ecuador 15
CL - Cile 13
CZ - Repubblica Ceca 12
JM - Giamaica 12
AE - Emirati Arabi Uniti 10
IE - Irlanda 10
KE - Kenya 10
PY - Paraguay 10
AZ - Azerbaigian 9
EE - Estonia 9
LT - Lituania 9
CR - Costa Rica 8
PE - Perù 8
AL - Albania 7
BO - Bolivia 7
IL - Israele 7
BJ - Benin 6
EU - Europa 6
PS - Palestinian Territory 6
RO - Romania 6
KG - Kirghizistan 5
MY - Malesia 5
PH - Filippine 5
TN - Tunisia 5
AO - Angola 4
DZ - Algeria 4
JO - Giordania 4
LV - Lettonia 4
NI - Nicaragua 4
OM - Oman 4
PT - Portogallo 4
BN - Brunei Darussalam 3
DK - Danimarca 3
HN - Honduras 3
HU - Ungheria 3
NP - Nepal 3
NZ - Nuova Zelanda 3
TH - Thailandia 3
UY - Uruguay 3
GD - Grenada 2
GR - Grecia 2
GY - Guiana 2
IR - Iran 2
MN - Mongolia 2
RS - Serbia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
ZW - Zimbabwe 2
A1 - Anonimo 1
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BH - Bahrain 1
BS - Bahamas 1
Totale 21.676
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.283
Ashburn 1.087
Fairfield 936
Hong Kong 927
Singapore 861
Ann Arbor 745
Santa Clara 723
Chandler 644
Dallas 634
Houston 607
Serra 523
Milan 466
Seattle 431
Beijing 406
Wilmington 372
Shanghai 362
Sofia 351
Cambridge 332
New York 258
Boardman 250
Ottawa 193
Los Angeles 190
Princeton 182
Jacksonville 176
Florence 154
Izmir 143
Lawrence 142
Medford 137
Munich 119
Nanjing 106
Hefei 100
Abidjan 85
Des Moines 81
Istanbul 81
London 63
Frankfurt am Main 62
Buffalo 61
Seoul 61
Dong Ket 58
São Paulo 57
Rome 56
Bremen 54
Redondo Beach 54
Ho Chi Minh City 53
San Diego 51
Dearborn 49
Tokyo 48
Bern 47
Pisa 45
Vienna 39
Redwood City 36
Turku 35
Dakar 33
Nanchang 32
Changsha 30
Hebei 30
San Jose 30
Shenyang 28
Boulder 26
Dhaka 25
Nuremberg 25
Brussels 24
Hanoi 24
Jüchen 24
Lancaster 24
Düsseldorf 22
Ogden 22
Kunming 20
Lagos 20
Council Bluffs 19
Fuzhou 19
Jiaxing 19
Warsaw 19
Belo Horizonte 18
Chicago 18
Guangzhou 17
The Dalles 17
Phoenix 16
Rio de Janeiro 16
Columbus 15
Helsinki 14
Norwalk 14
San Francisco 14
Stockholm 14
Tashkent 14
Jakarta 13
Nürnberg 13
Porto Alegre 13
Toronto 13
Curitiba 12
Quanzhou 12
Baghdad 11
Chennai 11
Denver 11
Hangzhou 11
Hyderabad 11
Jeddah 11
Montreal 11
Orem 11
Pune 11
Totale 15.893
Salva come PNG Salva come JPEG
Nome #
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 239
CD45 expression in low-grade B-cell non-Hodgkin's lymphomas 228
Identification of miRSNPs associated with the risk of multiple myeloma 226
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 219
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 210
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 204
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 201
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 199
Infliximab treatment of grade IV skin acute graft versus host disease 197
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 196
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk 194
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). 192
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. 192
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 188
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 187
Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. 187
Unexpected cardiotoxicity in haematological bortezomib treated patients 185
Dipeptidyl-Peptidase 4 (Cd26): a Possible Therapeutic Target in Covid-19 182
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). 180
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma 179
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients 177
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. 176
Association of PIM gene translocation and TELAML1 rearrangement., LEUKEMIA RESEARCH,vol. Leuk Res. 2007 Dec;31(12):1761-2 174
Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. 173
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization 173
Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. 172
Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma 171
CD229 expression on bone marrow plasma cells from patients with multiple myeloma and monoclonal gammopathies of uncertain significance 171
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 168
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib 168
A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13) 166
Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis. 165
Folic acid fortification and cancer risk 165
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma 164
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation 163
Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation. 162
INDUCTION OF COMPLETE MOLECULAR RESPONSE WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN®) IN B CELL NON HODGKIN’S LYMPHOMA PATIENTS AFTER THE ACHIEVEMENT OF A COMPLETE CLINICAL RESPONSE WITH CHEMOTHERAPY REGIMEN 162
Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk 162
Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma 162
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients 161
Other mechanisms to explain the role of reduced folate carrier in cancer 160
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 160
A whole blood flow cytometric method to evaluate F-actin polymerization in neutrophils 159
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS AND THEIR RELATIONSHIP WITH CLINICAL OUTCOME OF MANTLE CELL LYMPHOMA 158
Myelomatous meningitis evaluated by multiparameter flow cytometry : report of a case and review of the literature 158
Unusual association of endometrial cancer and multiple myeloma 156
MDR1 polymorphism influences the outcome of multiple myeloma patients 156
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia 153
Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. 152
NQO1*2 polymorphism and response to treatment in patients with multiple myeloma 151
Immune Reconstitution after Allogeneic Stem Cell Transplantation: a Pilot Flow-Cytometry Study for T-Cell Sub-Populations 151
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in ch 149
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study 149
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 149
Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation 147
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients 146
TNF-a Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib 145
CD69 Expression Predicts Favorable Outcome in Multiple Myeloma Patients Treated with VTD 145
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 145
MDR1 polymorphism influences the outcome of multiple myeloma patients 144
Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11) 144
The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation 144
Two Cases of Plasma Cell Leukemia with Atypical Immunophenotype 143
Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia 142
CD69, a New Potential Clinical Marker in Multiple Myeloma 142
Donor-transmitted Triple-Hit Lymphoma in a Renal Allograft Recipient 142
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. 141
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients 141
ZINC ORAL SUPPLEMENTATION INDUCES A SIGNIFICANT RISE OF TRECS AND T CD4+ NAΪVE AND PREVENTS THE INCREASE OF TTV VIRAL LOAD AFTER STEM CELL TRANSPLANTATION: THE ZENITH STUDY 140
Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients 138
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 138
Neoplasie degli organi emopoietici e linfatici: peculiarità dell'anziano 138
Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. 137
Folate levels in cancer: a vitamin for a new challenge 137
Piezoelectric signals in vascularized bone regeneration 137
Association of PIM gene translocation and TEL/AML1 rearrangement. 136
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 136
Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. 136
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma 135
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. 135
Cardiac light-chain deposition disease relapsing in the transplanted heart 135
The onset of monoclonal and oligoclonal gammopathies is a good prognostic factor after allogeneic stem cell transplantation 135
Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas. 134
CD45 expression in low-grade non-Hodgkin's lymphomas 134
Stable low IgG levels in relapsed non-Hodgkin's lymphomas 134
Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia 134
Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis. 133
Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. 133
Molecular Remission After VTD or TAD As Induction for Multiple Myeloma: Results with Two Different Methods of Analysis 133
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 133
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 133
The Role of Imaging in Relapse Detection During Follow up: a Fifteen-Year Single Center Experience. 131
ORAL CYCLOPHOSPHAMIDE AND RITUXIMAB IN THE TREATMENT OF MARGINAL ZONE LYMPHOMA 131
Folate levels and methylation of CDKI proteins 130
MDR1 modulates apoptosis in CD34+ leukemic cells 130
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis 130
PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patients 129
MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma 128
Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation 128
Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma 127
Totale 15.790
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.447
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.447
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021784 0 0 0 0 0 69 124 91 121 78 107 194
2021/20221.647 44 103 53 103 273 199 59 68 89 59 118 479
2022/20232.110 291 289 136 183 211 229 18 167 345 14 208 19
2023/20241.680 193 215 218 138 267 243 65 35 16 27 97 166
2024/20255.204 19 175 49 290 487 506 439 266 498 638 519 1.318
2025/20263.441 378 649 738 494 652 530 0 0 0 0 0 0
Totale 22.015